Best Life Sciences Companies in Chapel Hill, United States
The 60 best Life Sciences companies in Chapel Hill, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Cempra.
Our analysis of 164 Life Sciences companies
$34.7b in tracked funding; 83% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Life Sciences companies in Chapel Hill
| # | Company | Disclosed funding | Last round | Employees | Founder | Stage | Founded | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Cempra Clinical-stage pharmaceutical company focused on developing antibacterials | $154M | 142 mo ago | 78 | — | Series C | 2006 | — | — |
| 2 | G1 Therapeutics Developer of therapeutic solutions for the treatment of different cancer | $98M | 97 mo ago | 100 | — | Acquired | 2008 | 1,876 patents Patents concentrated in chemistry & materials | — |
| 3 | Cardioxyl Pharmaceuticals Clinical stage biopharmaceutical company | $66M | 163 mo ago | 11 | Chris Boerner Board Chair and Chief Executive Officer | Acquired | 2005 | 308 patents Patents concentrated in health & consumer products | — |
| 4 | Atox Bio Developer of immunomodulators for treatment of rare disease | $59M | 103 mo ago | 6 | Gila Arad Co-Founder | Deadpooled | 2003 | — | — |
| 5 | Bamboo Therapeutics Developer of gene therapies to treat rare central nervous system and neuromuscular diseases | $49M | 124 mo ago | 27 | — | Acqui-Hired | 2014 | — | — |
| 6 | Tolerance Bio Developer of thymus-based therapies for immune-mediated diseases to increase healthspan | $37M | 18 mo ago | — | Holger Russ Scientific Co-Founder | Seed | 2023 | — | — |
| 7 | Vascular Pharma Pioneering diabetes treatments, focusing on diabetic nephropathy and improving patient lives | $35M | 126 mo ago | 2 | — | Series A | 2005 | — | — |
| 8 | Renovion Restoring lung health through innovative therapies for chronic respiratory diseases | $26M | 39 mo ago | 6 | — | Series B | 2013 | 66 patents Antioxidant pharmaceutical formulations using vitamin C and glutathione for respiratory therapies | — |
| 9 | Mucommune R&D firm advancing immunology, drug delivery, and mucosal biology innovations 9Funding top 33%Moat bottom 49%Talent bottom 45%Patents bottom 35% All 7 signals ▾Fundingtop 33% Moatbottom 49% Talentbottom 45% Patentsbottom 35% Globalbottom 35% Marketbottom 20% Innovationbottom 17% Funding: Raised $19.4M across 13 rounds · 13 rounds over 10 yrs (1.3/yr) Moat: Editorial + unicorn rating 1/10 · IP moat: 6 patents rank vs industry peers · Fliar Intelligence Index 9/100 | $19M | 9 mo ago | 12 | Sam Lai Founder | Funding Raised | 2015 | 6 patents Patents concentrated in chemistry & materials | — |
| 10 | Biofluidica Provider of liquid biopsy tests using CTCs | $18M | 51 mo ago | 13 13 → 7 (-46%) | Steven Soper Co-Founder & CTO | Series B | 2007 | 20 patents Microfluidic platforms for high‑efficiency isolation of rare biomarker and fetal cells | — |
| 11 | Doron Therapeutics Provider of therapeutics for orthopedic indications | $11M | 19 mo ago | — | Alessandra Pavesio Co-Founder & CEO | Series A | 2023 | — | — |
| 12 | Sonovascular eveloper of a medical device to treat arterial and venous diseases | $8M | 5 mo ago | 8 | Daniel Estay Founder & CEO | Series A | 2017 | 7 patents Intravascular ultrasound catheter technology for enhanced imaging and therapeutic delivery. | — |
| 13 | NanoCor Therapeutics Developer of targeted drug delivery system for the treatment of CHF | $8M | 226 mo ago | — | Sheila Mikhail CEO | Deadpooled | 2005 | — | — |
| 14 | Create Wellness Provider of creatine monohydrate gummies to support overall well-being | $7M | 3 mo ago | 8 | Sienna McCormick Co-Founder & Co-CEO | Series B | 2022 | — | 1 launch |
| 15 | Meryx Pharma Developing orally bioavailable cancer drugs targeting Mer Tyrosine kinase receptor. | $7M | 132 mo ago | 3 | — | Deadpooled | 2013 | — | — |
| 16 | AnelleO Provider of 3D-printed healthcare products for women | $7M | 33 mo ago | 2 | Rima Janusziewicz Co-Founder | Funding Raised | 2017 | — | — |
| 17 | OncoTrap Developer of in vivo nucleic delivery technology and de novo protein engineering technology | $5M | 33 mo ago | 5 | — | Deadpooled | 2017 | — | — |
| 18 | Annias Immunotherapeutics Developing therapeutic vaccine targeting a strain of Cytomegalovirus (CMV) that is harbored in many solid… | $4M | 129 mo ago | — | Reiner Laus President & CEO | Funding Raised | 2015 | — | — |
| 19 | Achelios Developing topical medications for pain and inflammation relief | $4M | 122 mo ago | 6 | Crist Frangakis President & CEO | Series A | 2012 | — | — |
| 20 | EpiCypher Provider of epigentic kits, reagents and assays for research purpose | $3M | 10 mo ago | 43 | — | Series A | 2012 | 66 patents Chromatin profiling tools: nucleosome barcoding, modification quantification, and high‑throughput assays | 1 partnership |
| 21 | Bio 54 Developer of a therapeutic device for the treatment of bleeding | $3M | 56 mo ago | — | Meg Powell Founder & CEO | Series A | 2021 | — | — |
| 22 | Synereca Developing drugs that restore or increase the effectiveness of existing antibiotics | $3M | 106 mo ago | 7 | — | Deadpooled | 2009 | — | — |
| 23 | Exodos Life Sciences Topical medications for pain and inflammation | $2M | 149 mo ago | — | — | Deadpooled | 2009 | — | — |
| 24 | Caeregen Therapeutics Developer of regenerative medicine for retinal disorders | $2M | 82 mo ago | 1 | Kimberly Drenser Co-Founder | Funding Raised | 2010 | — | — |
| 25 | Enzerna Developer of novel molecular tools to modulate gene expression in any organism | $1M | 46 mo ago | 9 | — | Funding Raised | 2014 | — | — |
| 26 | Neochromosome Genome-scale biological engineering enabling cell-based manufacturing and antibody discovery | $1M | 60 mo ago | 28 | — | Funding Raised | 2012 | 6 patents Patents concentrated in chemistry & materials | — |
| 27 | Zumatek 3D imaging technologies for lesion detection | $923K | 187 mo ago | — | Randolph McKinley Co-Founder & CEO | Deadpooled | 2005 | — | — |
| 28 | BioKier Oral pills to treat for diabetes and related disorders. | $580K | 23 mo ago | 3 | George Szewczyk CEO and CSO | Seed | 2008 | 85 patents Metabolic disease therapeutics focusing on cholesterol, diabetes, and gut‑targeted microbiome modulation | — |
| 29 | Ternalys Developer of therapeutics for cancer treatment | $552K | 16 mo ago | — | Pierpaolo Peruzzi Co-Founder | Funding Raised | 2021 | — | — |
| 30 | Next Ray Diffraction Enhanced Imaging devices | $536K | 197 mo ago | — | Christopher Parham Co-Founder | Deadpooled | 2007 | — | — |
| 31 | Neuronano Pharma Developer of formulation and drug delivery technologies | $440K | 103 mo ago | — | Zagit Gaymalov Co-Founder & CEO | Funding Raised | 2011 | — | — |
| 32 | Redbud Labs Manufacturer of microfluidic platforms for biosensing and sample processing | $305K | 15 mo ago | 20 | — | Series A | 2010 | 101 patents Patents concentrated in transport & manufacturing processes | — |
| 33 | Kalia Health Developer of a home-based prenatal diagnostic test | $250K | 48 mo ago | 7 | — | Seed | 2017 | — | — |
| 34 | Agile EndoSurgery Endoscopic surgical devices for minimally invasive surgery | $234K | 135 mo ago | — | Adam Steege Founder & CTO | Deadpooled | 2010 | 17 patents Advanced endoscopic surgical instruments for minimally invasive procedures. | — |
| 35 | Theultraloop.com Developer of UV-C-based technology solutions for healthcare industries | $225K | 57 mo ago | 8 | Yash Bansal Co-Founder And Cto | Seed | 2021 | — | — |
| 36 | Auration Biotech Developer of therapeutics for the treatment of ear, nose, and throat diseases | $200K | 58 mo ago | — | Sanjay Chanda Co-Founder | Funding Raised | 2014 | — | — |
Top 12 Life Sciences companies in Chapel Hill
#1
Series B · Chapel Hill, North Carolina · founded 2022 · 8 employees$7.3Mraised▾
Provider of creatine monohydrate gummies to support overall well-being. The company is offering Creatine gummies that can improve muscle performance, particularly during high-intensity, short-duration exercises.
- Mar 2026Series B$20M
- Jul 2024Series A$7.3M
#2
Series A · Chapel Hill, North Carolina · founded 2017 · 8 employees$8.3Mraised▾
Developer of a medical device to treat arterial and venous diseases. It offers multi-mechanism thrombectomy system for the endovascular treatment of diseases which include deep vein thrombosis, pulmonary embolism, peripheral artery occlusion, and acute ischemic stroke.
- Feb 2026Series A$6M
- Jul 2023Seed—
- Jan 2023Conventional Debt$2.2M
- Aug 2020Grant (prize money)$150K
#3
Funding Raised · Chapel Hill, North Carolina · founded 2015 · 12 employees$19.4Mraised▾
R&D firm advancing immunology, drug delivery, and mucosal biology innovations. This organization specializes in translating early-stage academic discoveries into preclinical studies and clinical development, bridging the gap between research and practical application. It focuses on unmet needs in female reproductive health and tackling polymer immunogenicity. Technologies advanced include mAb therapies for respiratory infections and interventions for female reproductive health. This company operates as a specialty R&D operation, emphasizing innovation in immunology, drug delivery systems, and mucosal biology. It aims to develop first-in-class interventions and advance scientific breakthroughs into tangible healthcare solutions. The company spun off a biopharma company to commercialize treatments for acute respiratory infections.
- Sep 2025Grant (prize money)$1.1M
- Aug 2025Grant (prize money)$306.5K
- Mar 2025Grant (prize money)$380.7K
- Feb 2025Grant (prize money)$306.5K
#4
Series A · Chapel Hill, North Carolina · founded 2012 · 43 employees$3.4Mraised▾
Provider of epigentic kits, reagents and assays for research purpose. Its products include antibodies, cell extracts, histone peptide arrays, histone peptides, nucleosomes, peptide synthesis, and recombinant proteins. It also, offer Cutana cut and Run assays, which are an alternative to ChIP assays and offer advantages such as reduced cell input and diverse target profiling.
- Sep 2025Grant (prize money)$2M
- May 2025Grant (prize money)$2M
- Apr 2025Grant (prize money)$2.5M
- Feb 2025Grant (prize money)$1.4M
#5
Seed · Chapel Hill, North Carolina · founded 2023$37.4Mraised▾
Developer of thymus-based therapies for immune-mediated diseases to increase healthspan. It focuses on preserving, restoring, and manipulating the function of the thymus. The thymus is a master regulator of immune tolerance. The company aims to control immune tolerance by influencing thymus function.
- Dec 2024Seed$20.2M
- Oct 2024Seed$17.2M
#6
Series A · Chapel Hill, North Carolina · founded 2023$11Mraised▾
Provider of therapeutics for orthopedic indications. It offers a lead product MOTYS an intra-articular biologic drug derived from placental tissue. It delivers a host of beneficial growth factors with potent anti-inflammatory, tissue-protective and regenerative capabilities pivotal to the progressive and degenerative disease of osteoarthritis.
- Nov 2024Series A$11M
#7
Funding Raised · Chapel Hill, North Carolina · founded 2021$551.5Kraised▾
Developer of therapeutics for cancer treatment. It offers SAGUARO technology that provides microRNA replacement therapy, which include a lead candidate (TT-003) for the treatment of glioblastoma via intratumoral delivery.
- Mar 2025Grant (prize money)$275.8K
- Sep 2022Grant (prize money)$275.8K
#8
Series B · Chapel Hill, North Carolina · founded 2013 · 6 employees$25.8Mraised▾
Restoring lung health through innovative therapies for chronic respiratory diseases. This clinical-stage company is dedicated to advancing therapies that address mucus accumulation, inflammation, and bacterial infection in lung diseases. Their lead product, ARINA-1, is being developed to improve the lives of individuals with lung transplant, non-cystic fibrosis bronchiectasis (NCFBE), and chronic bronchitis (CB). They focus on restoring mucociliary clearance, downregulating inflammation, and inhibiting bacterial growth in the lungs. By targeting these key issues, they aim to improve the quality of life for patients suffering from chronic inflammatory airways diseases. They are involved in clinical trials and research to further develop and validate their therapies. The company partners with organizations like the COPD Foundation to design trials and meet the needs of patient populations with limited treatment options.
- Mar 2023Series B$15M
- Jul 2020Grant (prize money)$1.2M
- May 2020Series A$8.1M
- Feb 2019Seed$492.2K
#9
Series A · Chapel Hill, North Carolina · founded 2010 · 20 employees$305Kraised▾
Manufacturer of microfluidic platforms for biosensing and sample processing. The company's platform uses actuated surface-attached posts (ASAPs), which are micro-posts that bend in the presence of magnetic fields and are capable of fluid handling applications. ASAPs have a diameter less than that of a bacterium and can promote the manipulation of fluids, cells, and reagents. Its applications include life science research and the development of clinical diagnostics.
- Mar 2025Grant (prize money)$2.5M
- Mar 2025Grant (prize money)$2M
- 2022Grant (prize money)$3.3M
- 2021Grant (prize money)$1.3M
#10
Series C · Chapel Hill, North Carolina · founded 2006 · 78 employees$154.5Mraised▾
Cempra develops novel, well-differentiated antibiotics to meet critical unmet medical needs. Two lead products - Solithromycin (CEM-101) and TAKSTA (CEM-102, Sodium Fusidate), both in clinical-stage development, address the need for new treatments targeting drug-resistant bacterial infections in both the hospital and the community.
- Sep 2014Post IPO$10M
- Oct 2012Post IPO$25.1M
- Aug 2011Convertible Debt$5M
- May 2010Series C$46M
#11
Acquired · Chapel Hill, North Carolina · founded 2008 · 100 employees$97.6Mraised▾
Developer of therapeutic solutions for the treatment of different cancer. The company has its proprietary kinase drug discovery platform to advance a pipeline of first-in-class compounds and best-in-class drug candidates. Its drug pipeline includes G1T28, a CDK4/6 inhibitor that is being developed to reduce bone marrow and immune system damage caused by chemotherapy, and G1T38, a CDK4/6 inhibitor that is being developed to treat patients with CDK4/6-dependent tumors. Investigating G1T28 in clinical trials in patients with small-cell lung cancer and G1T38 in estrogen receptor breast cancer patients and castrate-resistant prostate cancer patients.
- Jun 2018Post IPO$38.4M
- Jul 2016Series C$50M
- Feb 2015Series B$33M
- Jun 2014Series A$12.6M
#12
Seed · Chapel Hill, North Carolina · founded 2008 · 3 employees$580Kraised▾
BioKier develops drugs for diabetes and related disorders. It offers oral pills for the treatment of type 2 diabetes, as well as for metabolic syndrome and obesity conditions. Its formulation mimics the effects of intestinal-shortening surgery and improves or resolves diabetes without the physical trauma and cost of bariatric surgery. Its approach is expected to be suitable for both obese and non-obese diabetes patients.
- Aug 2024Grant (prize money)$435.9K
- Aug 2015Grant (prize money)$4.7M
- Sep 2014Conventional Debt$230K
- Jul 2013Conventional Debt$645K
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Biotechnology is moving in the United States
A read on the academic research around Biotechnology — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 6,260 United States-affiliated papers.
- Harvard University209
- Cornell University177
- University of Tennessee at Chattanooga140
- Howard Hughes Medical Institute126
- Johns Hopkins University121
- Gene33→164
- Transcription (linguistics)11→79
- Antibody11→62
- Genome6→56
- Mutation7→56
- Gene8→110
- Cell culture3→62
- Gene expression3→62
- Fermentation2→54
- Downregulation and upregulation1→50
- Agriculture19→58
- Antibiotic resistance15→45
- Public health4→31
- Gene6→30
- Production (economics)5→29
Where biotechnology is researched across United States
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Who's filing biotechnology patents in the United States
United States biotechnology patent filing is accelerating — 457,918 filings from 8,000 assignees (2016–2025), led by Genentech, UNIV California, Regeneron Pharma; annual filings 36884→44446.
- Genentech18113
- UNIV California17975
- Regeneron Pharma16083
- Amgen10515
- Monsanto Technology9755
- UNIV Pennsylvania8528
- Harvard College7464
- UNIV Texas7384
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.